Immatics Reports Q2 2025 Financial Results and Business Update

Immatics ( (IMTX) ) just unveiled an announcement.

On August 13, 2025, Immatics N.V. released its financial results for the second quarter of 2025, revealing a significant increase in research and development expenses compared to the previous year. The company reported a substantial operating loss, reflecting its continued investment in advancing its pipeline of cancer immunotherapies. Despite the financial losses, Immatics remains committed to its strategic goals and continues to update stakeholders with its latest investor presentation.

The most recent analyst rating on (IMTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.

Spark’s Take on IMTX Stock

According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.

Immatics’ overall stock score is driven by its financial performance challenges and negative valuation signals, which are partially offset by positive technical indicators. The company’s profitability and cash flow issues weigh heavily on its score, despite some positive momentum in the market.

To see Spark’s full report on IMTX stock, click here.

More about Immatics

Immatics N.V. is a biotechnology company based in Tübingen, Germany, specializing in the development of T-cell receptor-based immunotherapies for cancer treatment. The company focuses on advancing its proprietary platforms, including XPRESIDENT and ACTengine, to discover and develop novel cancer immunotherapies.

Average Trading Volume: 586,572

Technical Sentiment Signal: Hold

Current Market Cap: $780.4M

See more data about IMTX stock on TipRanks’ Stock Analysis page.